Document is current

Article History

First Online: 12 June 2018

Compliance with Ethical Standards

: All patients provided written informed consent for reuse of their clinical data. For this survey, no approval from an ethics committee was necessary.

: This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors.

: Zecca C.: The Department of Neurology, Regional Hospital Lugano (EOC), Lugano, Switzerland receives financial support from Biogen, Genzyme, Merck, Novartis, Roche, Teva. Gobbi C.: The Department of Neurology, Regional Hospital Lugano (EOC), Lugano, Switzerland receives financial support from Biogen, Genzyme, Merck, Novartis, Roche, Teva. Antozzi C.G. received funding for travelling for congress attendance from Biogen, Merck, and Teva. Torri Clerici V. acted as an Advisory Board member for Biogen, Merck, Novartis, and Genzyme and received funding for travel from Biogen, Merck, Bayer, Genzyme, and Almirall and honoraria for speaking or writing from Merck, Teva, Genzyme, and Almirall. She received support for a research project from Almirall and is involved as principal investigator in clinical trials for Novartis and FISM. Confalonieri P.A. acted as an Advisory Board member for Biogen and Novartis; received funding for travel from Biogen, Merck, Teva, and Novartis; and received honoraria for speaking or writing from Biogen and Novartis. He received support for research projects from Novartis and Merck and is involved as principal investigator or co-investigator in clinical trials for Teva, Novartis, Biogen and Merck. Mantegazza R.E. acted as an Advisory Board member for Biomarin, and received funding for travel or speaker honoraria from Sanofi-Aventis, Biomarin, Grifols, Teva, Bayer, Alexion, and Argenx. He is involved as principal investigator in clinical trials for Alexion, Merck Serono, Hoffman-La Roche, Teva, Besta-Azienda Ospedaliera San Gerardo, Biogen, Biomarin, Almirall, Novartis, Genzyme Corporation, and Catalyst. Rossi S. acted as an Advisory Board member for Biogen, Bayer Schering, Merck, Teva, Novartis, Genzyme, and Mylan; received travel funding from Biogen, Merck, Teva, Novartis, Bayer Schering, Genzyme, and Almirall; and received honoraria for consultancy, speaking or writing from Biogen, Merck, Teva, Novartis, Bayer Schering, Genzyme, and Roche. She received support for research projects from Teva, Merck and Bayer Schering and is involved as principal investigator in clinical trials for Teva, Novartis, Biogen, and Roche. Bellavia G., Brambilla L., Gutierrez L.P., Gerardi C., Fiori A.M., Bernardini L.R., Disanto G., Petrini L., Perugini J., Bellino A., and Camera G. declare that they have no conflict of interest.